Overview

Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression

Status:
Completed

Trial end date:
2017-07-19

Target enrollment:

Participant gender:

Summary

This study investigates the efficacy of a fixed-dose regimen of cariprazine 1.5 milligram (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.

Phase:

Phase 3

Details

Lead Sponsor:

Forest Laboratories
Forest Laboratories, LLC, an Allergan Affiliate

Treatments:

Cariprazine